Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1110

Shown on this page

Current sort

Live official records

Conditions: Peritoneal Malignant Mesothelioma
Interventions: Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Pemetrexed Disodium, Positron Emission Tomography; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 40
States / cities: Phoenix, Arizona • Chicago, Illinois • Danville, Illinois + 31 more

Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions: Vaginal Fluid Collection, Blood Collection; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 21 more

Conditions: Short Bowel Syndrome
Interventions: Glepaglutide, Placebo; Drug · Other
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 6
States / cities: Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 3 more

Conditions: Hypertension
Interventions: lorundrostat, Placebo; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 128
States / cities: Birmingham, Alabama • Foley, Alabama • Chandler, Arizona + 101 more

Conditions: HIV Treatment
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ulcerative Colitis
Interventions: RO7837195, RO7837195 Matched Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more

Conditions: Moderately to Severely Active Crohns Disease
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 61
States / cities: Dothan, Alabama • Glendale, Arizona • Lancaster, California + 55 more

Conditions: Breast Cancer
Interventions: Stool Sampling, Chia Seeds; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Abdominal Aortic Aneurysm
Interventions: Nectero EAST System; Drug
Lead sponsor: Nectero Medical, Inc.; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 40
States / cities: Scottsdale, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 32 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Tacabrutideg, Pirtobrutinib; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 42 more

Conditions: Ductal Carcinoma in Situ
Interventions: Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen; Drug
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 29
States / cities: Berkeley, California • Duarte, California • Irvine, California + 22 more

Conditions: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radium Ra 223 Dichloride; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 47
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more

About this University of Chicago Medicine institution page

What this page lists: ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Chicago Medicine

Filter and sort this campus

Live official records

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Building Rapid Inpatient Delivery of ART to Generate Engagement in HIV Care

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment

Nectero EAST System Clinical Study

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

About this University of Chicago Medicine institution page